Vertex Pharma Says Kalydeco Showed Lung Function Improvement, Improvements Durable Up to 96 Weeks

Vertex Pharmaceuticals Incorporated VRTX announced today new data from a long-term follow-up study that showed that the improvements in lung function (forced expiratory volume in one second, FEV[1]), respiratory symptoms and weight gain among people who were treated with KALYDECO™ (ivacaftor)for 48 weeks in one of two pivotal studies (STRIVE or ENVISION) were durable for up to 96 total weeks of treatment